Core Viewpoint - China is significantly advancing its traditional Chinese medicine (TCM) service system, establishing the world's largest traditional medicine service framework, with substantial growth in healthcare institutions and patient visits by the end of 2024 [1]. Group 1: Growth Metrics - By the end of 2024, the number of TCM healthcare institutions, hospitals, and total patient visits will have increased by 43.3%, 16.7%, and 58.9% respectively compared to the end of the 13th Five-Year Plan [1]. - The TCM service system is expanding in both capacity and quality, enhancing the supply of high-quality TCM services [1]. Group 2: Project Initiatives - In 2025, China will support 450 county-level TCM hospitals to develop the "two specialties and one center" project, further solidifying and expanding grassroots TCM services [1]. - An additional 90 national TCM specialty areas will be established, including mental health, pediatrics, and gynecology, along with the launch of 57 suitable TCM disease categories for payment by disease type [1]. Group 3: Collaborative Development - The establishment of flagship hospitals and departments for collaborative TCM and Western medicine will focus on major difficult diseases, with 212 clinical collaboration projects planned [1]. - In 2025, the first national artificial intelligence application pilot base for TCM diagnosis and treatment services will be built, alongside 12 pilot projects for "smart TCM" [1].

Investment Insights - The report highlights that the pharmaceutical index observed negative returns across six sub-industries during the week [1] - China's biopharmaceutical industry is transitioning from a "rapid expansion" phase (1.0 era) to a "value and global competitiveness" phase (2.0 era), marking its emergence as the second-largest new drug launch market globally [1][6] - By 2025, the external licensing transaction value is expected to exceed $50 billion, with China establishing a leadership position in disruptive technologies such as targeted protein degradation [1][6] Industry Overview - China accounted for 18% of the global share of new molecular entities (NME) launched in 2024, ranking second worldwide [6] - The number of new drug pipelines in China represents approximately 30% of the global total, maintaining its position as the second-largest globally [6] - In the targeted protein degradation (TPD) field, China contributes 38% of global research papers and 37% of patents, with around 30% of the 484 TPD candidates in development originating from China [6] Market Performance - The report notes that the biopharmaceutical sector's performance was mixed, with traditional Chinese medicine and biological products experiencing declines of -1.94% and -2.50%, respectively [8] - The highest valuation levels were recorded for biological products (91.41 times) and chemical pharmaceuticals (79.85 times), while traditional Chinese medicine and pharmaceutical commerce had lower valuations of 31.70 times and 22.42 times, respectively [8] Future Outlook - The industry is expected to face both opportunities and challenges as it enters the new "14th Five-Year Plan" cycle, with a trend towards "the rich getting richer" and a focus on source innovation and global expansion [7] - Key challenges include resource misallocation due to concentrated research on popular targets, high R&D costs, and the need for improved international capabilities among many companies [7]

Core Insights - The Chinese traditional medicine service system has significantly expanded and improved in quality over the past year, with a focus on enhancing high-quality service supply [1][2] - The 2026 National Traditional Chinese Medicine (TCM) Bureau Directors' Conference highlighted various initiatives aimed at promoting TCM, including the establishment of specialized departments and pilot projects [1][2] Group 1: Expansion and Quality Improvement - 90 new specialized departments in areas such as mental health, pediatrics, and gynecology have been added to the national TCM advantage specialties [1] - The number of TCM medical institutions, hospitals, and total patient visits increased by 43.3%, 16.7%, and 58.9% respectively compared to the end of the 13th Five-Year Plan [2] Group 2: Future Plans and Initiatives - In 2026, China will issue the "15th Five-Year Plan" for TCM revitalization and development, along with several specialized plans [2] - The country will implement a medical and health foundation project focusing on TCM, promoting the establishment of tightly-knit county-level medical communities led by county TCM hospitals [2] Group 3: Talent Development - The TCM talent pool is expanding, with 73 TCM training and assessment bases established and over 22,000 individuals passing the TCM training graduation exam [1] - 54 candidates for the Qihuang Scholar training program and 500 candidates for the national TCM clinical excellence training program have been selected [1]

Company Overview - The company, Hangzhou Gan Zhi Cao Technology Co., Ltd., is a leading online traditional Chinese medicine (TCM) service provider in China, focusing on online TCM diagnosis and treatment services, TCM medical institution services, and TCM health products [3][4] - Established in 2015, the company is one of the earliest online TCM service providers in China, holding a 4.9% market share, making it the largest player in the online TCM comprehensive service market [3][4] - The company has developed its own online diagnosis platform, Gan Cao Doctor, and a SaaS and supply chain service system, Gan Cao Cloud Manager, to enhance service delivery [4][5] Market Position - According to a report by Frost & Sullivan, the company ranks first in the online TCM diagnosis service market with a 16.7% market share as of 2024 [3] - The overall market for online TCM services is expected to grow significantly, with the online comprehensive TCM service market projected to expand from RMB 2.7 billion in 2019 to RMB 13 billion by 2024, reflecting a compound annual growth rate (CAGR) of 36.5% [10][12] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately RMB 603 million, RMB 690 million, and RMB 554 million, respectively [5][6] - The profit and total comprehensive income for the same periods are RMB 1.875 million, RMB 10.156 million, and a loss of RMB 1.235 million, respectively [6] - The gross profit margin for the same periods is 22.8%, 23.4%, and 27% [7] Industry Overview - The TCM industry in China is projected to grow from RMB 1,079.4 billion in 2019 to RMB 1,448.6 billion by 2024, with a CAGR of 6.1% [10] - The TCM diagnosis service segment is expected to reach approximately RMB 1,001.6 billion by 2024, growing at a CAGR of 10.1% [12] - The overall TCM market is transitioning from a drug-centric model to a more integrated healthcare and wellness development paradigm, supported by favorable policies and technological integration [12]

Group 1 - The core viewpoint of the article is that Hangzhou Gan Zhicao Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to capitalize on its leading position in the online traditional Chinese medicine (TCM) service market [1] - According to a report by Frost & Sullivan, the top five online TCM service providers in China hold a combined market share of 10.7% based on projected 2024 revenue, with Gan Zhicao leading at 4.9% [1] - Gan Zhicao also ranks first in the online TCM diagnosis service market with a market share of 16.7% based on projected 2024 revenue, indicating its dominance in this key segment [1] Group 2 - The company is described as a leading online TCM service provider driven by digital intelligence, focusing on online TCM diagnosis services and expanding into a full industry chain that includes TCM diagnosis, medical institution services, and health products [3]

Core Viewpoint - The implementation of the "Zhengzhou Traditional Chinese Medicine Development Promotion Regulations" marks a significant step towards the legalization and standardization of traditional Chinese medicine (TCM) in Zhengzhou, effective from March 1, 2026, addressing public health needs and development challenges in the TCM sector [1][2]. Group 1: Legislative Framework - The new regulations aim to transform policy deployment into legal frameworks, providing legal guarantees for the establishment of a national TCM innovation development pilot zone and enhancing the Zhengzhou Qihuang cultural brand [2][3]. - The regulations address core issues such as service systems, industry development, and talent cultivation, establishing specific chapters for regulation [3]. Group 2: Industry Development - The regulations support the establishment of TCM research platforms and the transformation of TCM achievements into industrial applications, including the construction of regional TCM preparation centers and standardized preparation rooms in medical institutions [3][4]. - The integration of TCM with other industries such as food, culture, tourism, and health is encouraged to create a new ecological model for TCM industry in Zhengzhou [3]. Group 3: Talent and Technology Empowerment - A multi-level talent system is being developed, focusing on high-end, mid-level, and grassroots talent cultivation, with the introduction of high-end talent teams [5]. - The integration of artificial intelligence with TCM services, research, and regulation is highlighted as a new focus area, aiming to create a smart TCM ecosystem [5][6]. Group 4: Quality and Safety Measures - The regulations mandate the establishment of a quality traceability system for TCM materials, ensuring safety and quality throughout the supply chain [4][8]. - Measures to combat counterfeit products and promote international TCM cultural exchange are included to enhance Zhengzhou's global influence in TCM [4]. Group 5: Infrastructure and Investment - The government plans to clarify departmental responsibilities and promote collaboration among various departments to strengthen the grassroots TCM service foundation [8]. - Investment in infrastructure, talent, and research is prioritized, along with the optimization of medical insurance payment policies to reflect the value of TCM [8].

Core Viewpoint - The Chinese traditional medicine industry is undergoing unprecedented transformation, necessitating a shift towards digitalization to enhance supply capabilities and lead the industry into a new application era [1] Industry Development - The 2025 China Traditional Medicine 50-Person Summit was held on September 13 during the 2025 China International Service Trade Fair, marking its third consecutive year at the event [1] - The National Administration of Traditional Chinese Medicine, in collaboration with the National Data Bureau, released guidelines in 2024 to promote the development of digital traditional medicine, establishing "digital traditional medicine" as a national strategic goal [1] Forum Objectives - The forum focused on industry development needs and cutting-edge advancements, themed "Digital Technology and the Future of Traditional Medicine," aiming to facilitate deep integration between traditional medicine and digital technology [1] - The goal is to accelerate the digital transformation of the traditional medicine industry, fostering new momentum and advantages for its development [1] Strategic Collaborations - The Beijing Shouchuang Traditional Medicine Development Foundation, Beijing Traditional Medicine Association, China Medicinal Cuisine Research Association, and Guangzhou Pharmaceutical Group signed a framework agreement for strategic cooperation in areas such as food-medicine integration and special medical foods [1] - These organizations will leverage their strengths to promote the development of public welfare in traditional medicine through collaborative construction and research platform initiatives [1] - A project was signed between the Xiyuan Hospital of the China Academy of Chinese Medical Sciences and Tianjin Baoheng Biotechnology Co., focusing on a fermented beverage to alleviate visual fatigue, exemplifying successful transformation in food-medicine integration projects [1]

Group 1 - The 2025 China Traditional Chinese Medicine (TCM) 50-Person Summit was held on September 13 during the 2025 China International Fair for Trade in Services, marking its third consecutive year at the event [1] - The TCM industry is undergoing an unprecedented transformation, necessitating a shift towards digital intelligence to enhance supply capabilities and lead TCM into a new application era [1] - The National Administration of Traditional Chinese Medicine, in collaboration with the National Data Bureau, released opinions in 2024 to promote the development of digital TCM, establishing the creation of a "Digital Intelligent TCM" system as a national strategic goal [1] Group 2 - A framework agreement was signed among Beijing Shouchuang TCM Development Foundation, Beijing TCM Association, China Medicinal Food Research Association, and Guangzhou Pharmaceutical Group to collaborate in the fields of food-medicine integration and special medical foods [2] - The collaboration aims to leverage each party's strengths to advance the construction and research platform in the food-medicine integration and special medical food sectors, promoting the development of TCM public welfare [2] - A signing project was completed between the China Academy of Chinese Medical Sciences Xiyuan Hospital and Tianjin Baoheng Biotechnology Co., focusing on a fermented beverage to assist in alleviating visual fatigue, representing a successful transformation of food-medicine integration projects [2]

Core Viewpoint - The "Yuan Cheng Chan Yuan" integrated development plan aims to enhance the traditional Chinese medicine (TCM) industry in Henan Province by establishing a comprehensive research and innovation system by 2027, including 20 research institutes and a TCM industry park [1][2] Group 1: Policy and Strategic Framework - The Zhengzhou Airport Economic Comprehensive Experimental Zone has issued a work plan to promote high-quality development of the TCM industry, focusing on transforming TCM resource advantages into industrial and economic advantages [1] - The plan emphasizes the integration of TCM research resources and aims to establish a global first for a TCM and Western medicine combined medical science city [1][2] Group 2: Industry Development Focus - The work plan highlights key tasks and major projects to lead the construction of a strong TCM province, with a focus on TCM innovation, "TCM+" health consumption upgrades, and specific sub-industries such as TCM new drug development and deep processing of medicinal materials [1][2] - The plan aims to create a one-stop public service system centered around the TCM industry park, addressing key challenges in the TCM industry chain, including resource development and quality enhancement [2] Group 3: Innovation and Ecosystem Building - The initiative will focus on four main areas: advancing TCM technology innovation, upgrading the TCM industry, enhancing ecological empowerment, and implementing pilot projects for TCM [2] - The Central Plains Medical Science City TCM industry park is designed to be a hub for TCM scientific innovation and industry aggregation, leveraging Henan's cultural and medicinal resource advantages [2]